The global anal fistula therapeutics market is estimated to grow at a CAGR of nearly 4.0% during the forecast period. Rising incidences of inflammatory bowel disease (IBD) is the major factor encouraging the demand for anal fistula therapeutics. As per the Centers for Disease Control and Prevention (CDC), in 2015, nearly 1.3% of the US adults (3 million) were reported being diagnosed with IBD (either ulcerative colitis or Crohn’s disease). This was a substantial increase from 1999 (0.9% or 2 million adults). As many as 70,000 new incidences of IBD are diagnosed in the US annually. IBD is the major risk factor of developing anal fistula.
Get Free Sample link @ https://www.omrglobal.com/request-sample/anal-fistula-therapeutics-market
There is a possibility of developing fistulas when an organ becomes injured or inflamed, which is a common complication of IBD, occurs more often in Crohn’s disease compared to ulcerative colitis. 35% of the patients with Crohn’s disease develop at least one fistula episode over the course of the condition. Fistula is most commonly located around the anus that is referred to as perianal fistulas. More than half of fistulas form in this location. Fistulas can also form in the perianal region or digestive tract after traumatic injury, surgery, or radiation therapy for cancer. Some conditions and infections can cause fistulas, including sexually transmitted disease and diverticulitis.
A full report of Global Anal Fistula Therapeutics Market available @ https://www.omrglobal.com/industry-reports/anal-fistula-therapeutics-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
Global Anal Fistula Therapeutics Market by Treatment
- Surgical
- Non-Surgical
Global Anal Fistula Therapeutics Market by Application
- Intersphincteric Fistula
- Transsphincteric Fistula
- Suprasphincteric Fistula
- Others
Global Anal Fistula Therapeutics Market by End-User
- Hospitals
- Ambulatory Surgical Centers
- Others
Regional Analysis
- North America
- United States
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Rest of the World
Company Profiles
- Medtronic plc
- Cook Group Inc.
- Takeda Pharmaceutical Co. Ltd.
- Karl Storz SE & Co. KG
- Biolitec AG
- Pfizer Inc.
- Becton, Dickinson and Co.
- GEM S.r.l.
- TiGenix NV
- L. Gore & Associates, Inc.
- AstraZeneca plc
- Agency for Medical Innovations (A.M.I.) GmbH
- Signum Surgical Ltd.
- Novartis International AG
- Assembly Biosciences, Inc.
- Ovesco Endoscopy AG
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global anal fistula therapeutics market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/anal-fistula-therapeutics-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
